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Minding your p's and q's
SH3 domains mediate many important protein-protein interactions. The
molecular basis of the binding of these domains to their ligands has been
revealed, making it possible to identify SH3-binding sites in new proteins.
Src homology 3 (SH3) domains have recently emerged as
the darlings of the. structural biology set. The three-
dimensional structures of no less than ten different SH3
domains have been solved by X-ray crystallography or
nuclear magnetic resonance spectroscopy (NMR), with
and without a variety of specific ligands. This wealth of
structural data provides a solid foundation for building
general models of SH3 domain-ligand interactions. The
time is now ripe to assess what we know about these
domains and their biological role, and, perhaps more
importantly, what still needs to be learned.
SH3 domains consist of approximately 60 amino acids
each, and are readily (and quite frequently) identified in
proteins by sequence similarity. The presence of SH3
domains in a wide variety of proteins - ranging front
cytoskeletal components, such as myosin I and the 
chain of spectrin, to signal-transduction enzymes, such as
non-receptor tyrosine kinases and phospholipase Cy -
suggested that the domain confers a modular function,
such as protein binding. This suspicion was confirmed
when it proved possible to isolate proteins from bacterio-
phage expression libraries that bound with high affinity in
vitro to labeled, bacterially produced SH3 domains [1]. It
was rapidly apparent that a variety of SH3 domains could
bind to short proline-rich peptides. The biological rel-
evance of such interactions was demonstrated when the
adaptor protein Grb2 - which contains only SH2 and
SH3 domains and is known variously as Sem-5, Drk and
ASH - was shown to bind via its SH3 domains to a pro-
line-rich region of the Ras activator protein Sos during
normal intracellular signaling in nematodes, fruitflies and
humans [2].
All SH3 domains have the same overall topology, consist-
ing of two small 13 sheets that are packed against each
other approximately at right angles (Fig. 1). There are
three variable loops revealed when SH3 domains are com-
pared, termed the RT, N-Src, and distal loops (this termi-
nology, like the name of the domain itself, refers to
features of the Src tyrosine kinase): the RT and N-Src
loops are on the ligand-binding face of the domain and
can modulate binding, whereas the distal loop is on the
opposite face and might interact with other regions of the
same protein. The peptide-binding surface of the SH3
domain consists of an elongated patch of aromatic residues,
which are well-suited to binding relatively hydrophobic
ligands such as proline-rich peptides. A similar patch of
surface aromatic residues was recently shown to mediate
the binding of poly-L-proline to the small actin-binding
protein profilin [3].
Proline-rich regions are a relatively common feature in
proteins, so it was critical to establish specific rules defin-
ing what sequences constitute high-affinity SH3 binding
sites, and what (if anything) determines specificity of bind-
ing among different SH3 domains. These issues were
attacked on a variety of fronts, most prominently by strat-
egies involving selection of random peptide ligands, mu-
tagenesis of known binding sites, and structural studies
of SH3 domain-peptide complexes [4-7]. These studies
showed that proline-rich ligands adopt the left-handed
polyproline-II helix (PPII) conformation, with two pro-
lines that are on the same face of the helix and separated
by two amino acids being critical for binding - the
so-called 'Pro-X-X-Pro' motif (where X is any amino
acid). An arginine residue three residues amino-terminal
to the Pro-X-X-Pro motif was often (but not always)
observed in high-affinity sites, and could be shown to
form a salt bridge with a conserved acidic residue found in
the RT loop of most SH3 domains. Thus, an initial con-
sensus binding site of Arg-X-X-Pro-X-X-Pro emerged,
in which the unspecified amino acids were usually either
prolines or other hydrophobic residues. These consensus
sequences are now termed class I sites.
A surprise came recently when Schreiber's group demon-
strated [8] that the SH3 domain of the Src kinase could
also bind to sites - termed class II sites - with the con-
sensus sequence Pro-X-X-Pro-X-Arg, and that these
peptides bound with opposite polarity to that seen for class
I ligands. At the same time, a host of papers on the three-
dimensional structure of the adaptor protein Grb2 showed
that its amino-terminal SH3 domain bound to peptides
derived from its natural ligand, Sos, in the class II orienta-
tion [9-12]. The admonition to the apprentice typesetter
- mind your p's and q's - suggests a fitting analogy for
SH3 domain-ligand recognition: the ability of the SH3
domain to bind its ligands in both amino-to-carboxyl and
carboxyl-to-amino orientations derives from the pseudo-
symmetry of the PPII helix. One can recast the ligand
consensus sequences as Arg-X-q-Pro-X-q-Pro for class I
sites and q-Pro-X-q-Pro-X-Arg for class II sites, to
reflect this symmetry (Fig. la). In these sequences, the 'q'
specifies any hydrophobic residue, but is often proline,
leucine or valine; the 'Pro' represents an essential proline
residue. The PPII helix is roughly triangular in cross sec-
tion (see Fig. 1). The 'q-Pro' sequences at the base of
the triangle intercalate with the conserved hydrophobic
residues of binding sites 1 and 2 on the surface of the
domain. The terminal charged residue, usually an arginine,
binds an acidic residue in site 3. The amino-acid side
chains at the apex of the triangle extend away from the
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Fig. 1. (a) The structures of class I and
class II peptide ligands are depicted
schematically. P and R indicate con-
served proline and arginine residues; q
and X indicate variable amino acids (see
text). (b) The three-dimensional struc-
ture of the SH3 domain from the Src-
family tyrosine kinase Fyn is shown
diagrammatically. The position of the
three variable loops and the three sites
on the surface of the SH3 domain that
contact ligand are indicated. The side
chains of residues involved in ligand
binding are depicted in colour, and cor-
respond to the boxes on the sequence
alignment shown in (c). (c) Alignment of
the amino-acid sequences of several
representative SH3 domains. Colored
boxes indicated conserved residues
involved in ligand binding. The posi-
tions of the RT, N-Src and distal loops,
and the 3 strands are indicated. CrkN
and GrbN are the amino-terminal SH3
domains of Crk and Grb2; N-Src is from
the alternatively spliced neural form of
Src; and PIK is from the p85 subunit of
phosphatidylinositol 3-kinase.
domain and can be any amino acid, but proline is com-
mon at these positions, probably because it stabilizes the
PPII conformation.
What determines which 'face' of the PPII helix packs
against the binding surface? The register of the arginine
with respect to the Pro-X-X-Pro sequence is a major fac-
tor. It has also been suggested that sites I and II select
'q-Pro' sequences over 'Pro-q' sequences because they are
more compact - two bonds, rather than three, separate
the hydrophobic side chains when the proline is in the
second position [8]. Also, the side chain of the non-prolyl
residues in the leading position usually adopts an 'internal'
packing conformation in which the side chain extends
into the binding site [11].
In class I binding, the amino-terminal arginine residue
occupies site 3, whereas in class II binding the orientation
of the peptide is reversed and a carboxy-terminal arginine
occupies this site. Interestingly, the two hydrogen bonds
between the SH3 domain and the peptide backbone are
conserved regardless of orientation [11]. In both types of
binding the 'q-Pro' sequences pack into sites 1 and 2, but
the positions of the prolyl and non-prolyl residues are
reversed within the sites (Fig. la). Because the 'q-Pro'
sequences are only roughly symmetrical, they are likely to
fit better into the binding pockets in one particular orien-
tation. Thus, the selection for class I or class II binding
modes lies in both the amino- or carboxy-terminal
position of the arginine residue and the subtle differences
in van der Waal's contacts within binding sites.
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Almost all of the residues of the SH3 domain that contact
the ligand are very highly conserved, defining the hydro-
phobic grooves that form sites 1 and 2 (Fig. lb). Different
SH3 domains select different optimal binding sites, how-
ever, and a particular proline-rich region of a protein will
bind preferentially to a subset of SH3 domains (see, for
example, [4]). How can this specificity be explained? The
first determinant of specificity seems to be site 3, which
interacts with arginine in SH3 domains from Src, p85 and
Grb2. The SH3 domain of the kinase Abl, however, does
not select arginine, but its high-affinity ligands instead
contain another turn of the PPII helix, and a proline
residue at position -5 relative to the Pro-X-X-Pro motif
bends in to occupy site 3. Structural studies showed that
the negatively charged residues that line site 3 in most SH3
domains are replaced by uncharged residues in Abl [5].
Unfortunately, virtually all other SH3 domains have an
acidic residue at the corresponding site, suggesting that
they would all bind positively charged ligands; notable
exceptions are the yeast Ras activators Cdc25 and Ste6,
and the Dig family of tight junction-associated proteins
that have guanylate kinase activity.
A more subtle form of specificity is seen in the case of the
SH3 domain of the adaptor protein Crk. This binds to
class II ligands with a preference for lysine instead of argi-
nine at position +2 relative to the Pro-X-X-Pro motif.
The crystal structure shows that the lysine makes an
unusual interaction where it is coordinated to three
precisely oriented carboxylate groups from acidic residues
in the RT loop; although arginine can also bind to this
site, the geometry is less optimal than in the case of lysine
[13]. It is interesting to note that the SH3 domains from
the Fyn, Lyn and Hck kinases all bind to a sequence in the
BTK kinase that seems to be a class I site containing lysine
instead of arginine at position +2, whereas the closely
related Src SH3 domain does not bnd this site well [14].
Fyn, Lyn and Hck each have an acidic residue in their RT
loop that is not present in the Src SH3 domain, suggesting
that binding to lysine-containing ligands might be com-
mon in cases where the SH3 domain has multiple acidic
residues in the binding pocket.
Beyond these limited specificities that might be predicted
from sequence comparisons, it is likely that other determi-
nants of specificity will be subtle and difficult to predict.
With the exception of the arginine or lysine that binds to
site 3, almost all SH3 domain-ligand contacts seen in the
published high-affinity structures involve van der Waal's
interactions or hydrogen-bonding to backbone atoms;
hydrogen-bonding or salt-bridging to ligand side chains is
seldom observed. Small differences in the packing of
hydrophobic side chains, however, might give differences in
binding energy sufficient to account for the differences
seen among SH3 domains. For example, the peptide
selected from a combinatorial library as optimal for binding
to the Src SH3 domain binds with only a two-fold higher
dissociation constant (Kd) to the phosphatidylinositol-3'
kinase SH3 domain; conversely the peptide able to bind
optimally to the phosphatidylinositol-3' kinase SH3
domain binds with a five-fold higher Kd to the Src SH3
domain [7]. These differences could easily be explained by
subtle changes in hydrophobic packing; such effects would
be impossible to predict from the primary structures of the
SH3 domain and the potential binding site.
One way that specificity might be generated in vivo is by
the additive effects of multiple potential binding sites and,
in some cases, multiple SH3 domains. Thus far, most
binding studies have used peptide substrates, and the disso-
ciation constants observed are above 1 uM. But many nat-
ural ligands for SH3 domains are embedded in long pro-
line-rich regions of more than 100 amino acids that
contain multiple potential binding sites. Tighter binding
(and higher specificity) can therefore be achieved because
the multiple potential binding sites make it less likely for
the SH3 domain to diffuse away without rebinding than in
the case of a monomeric ligand such as a peptide. Small
differences in the affinity of different SH3 domains for an
individual site would be magnified when multiple copies
of the site are present within a potential ligand.
In the case of the Abl-binding protein 3BP-1, five poten-
tial binding sites are present in a 105 amino-acid region,
and although it was possible to identify a minimal
10 amino-acid binding site, this binds the ligand more
weakly than does the whole protein containing multiple
sites [6]. The Sos protein, which binds the adaptor protein
Grb2, contains four binding sites in a 200 residue stretch
[15]; in this case, the avidity of binding might be height-
ened still further by the presence of two SH3 domains in
the intact Grb2 protein.
Beyond binding specificity, the most pressing questions
about SH3 domains concern the consequences of binding
and the ways in which binding might be regulated. In the
structures of liganded and unliganded SH3 domains that
are now available, few if any ligand-dependent differences
are seen, ruling out major conformational changes within
the domain. However, binding itself, by juxtaposing not
only the SH3 and its ligand but also other parts of what-
ever proteins each is embedded in, could have profound
effects on the activity of one or both proteins. Some
examples of binding-induced changes are the increase in
GTPase activity of the motor protein dynamin upon bind-
ing another protein's SH3 domain [4], and activation of
phosphatidylinositol 3' kinase by binding of SH3 domains
to its 85 kD subunit [16]. The specific mechanisms
involved in activation, however, will remain obscure until
the structures of such complexes are available.
There are also several examples of SH3 domains being
involved in regulating the activity of the proteins in which
they are found. For example, the Src family non-receptor
tyrosine kinases are each held in a catalytically inactive
conformation by binding of the SH2 domain to a car-
boxy-terminal regulatory phosphotyrosine residue. The
SH3 domain (found just amino-terminal to the SH2
domain) is required for this interaction to take place, prob-
ably facilitating the interaction by binding weakly to other
Src residues [17]. This implies that a regulatory event (such
as dephosphorylation of the tail peptide) would release the
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SH3 domain and make it available for interaction with
other proteins; on the other hand, high concentrations of a
high-affinity SH3 ligand in trans might destabilize the inac-
tive conformation, leading to activation. Interestingly, the
structure of the kinase Lck SH3-plus-SH2 domains co-
crystallized with phosphorylated tail peptide revealed that
the SH3-plus-SH2 portion of the molecule interacted in a
head-to-tail fashion with a second SH3-plus-SH2 mol-
ecule; the dimer interface was composed of residues from
the tail peptide, the SH3 domain and the SH2 domain
[18]. Although Src family kinases might not actually
dimerize in vivo, this structure illustrates how an SH3
domain might participate in intramolecular interactions,
involving distant regions of the protein, that would render
it inaccessible to other proteins.
This sort of cis-trans regulation - the existence of an
inactive, intramolecularly bound form and an activated,
binding-competent form - is likely to be a common
theme for SH3 domain-containing proteins. A good
example of such a scheme is found in the regulation of
superoxide generation in neutrophils. Two proteins,
p67Phx and p47phox, are required for activation of a mito-
chondrial oxidase; p47 and p67 contain two SH3 domains
each. Genes encoding components of this pathway are
often mutated in patients with hereditary chronic granulo-
matous disease (CGD); neutrophils from these people are
therefore unable to generate superoxide. Recent evidence
suggests that neutrophil activation causes p67 to bind, via
its SH3 domains, to the proline-rich tail of p4 7; the p4 7
SH3 domains bind, in turn, to a membrane-bound com-
ponent of the oxidase itself, termed p22ltx [19,20].
Binding of this whole complex to the membrane activates
the oxidase. Perhaps the clearest example yet of the
involvement of SH3 domain-ligand interactions in human
disease is provided by a mutation found in a CGD patient
that maps to the proline-rich region of p22 and abolishes
binding to p47. Intact p47 is normally unable to bind to
either p67 or p22, but when truncated, or treated in vitro
with arachidonic acid or sodium dodecyl sulphate (SDS),
its binding activity is unmasked [19]. Presumably, the mol-
ecule is normally held in an inactive conformation by
intramolecular interactions of SH3 domains with proline-
rich sequences, and these must be disrupted before the
complex can be assembled. It will be interesting to see
how p47 is normally activated in neutrophils.
As more and more protein sequences are deposited in the
database, is has become apparent that SH3 domains are
common protein motifs found in a wide range of interest-
ing proteins. Evidence from a variety of systems suggests
that these modules are workhorses of protein-protein
association. They are just the sort of thing that evolution
might exploit to organize the eukaryotic cytoplasm: of
moderate specificity, of moderate affinity and comfortable
in a variety of protein contexts, they can be fine-tuned to
fulfill a variety of roles in the regulation of proteins or the
assembly of multiprotein complexes. We are now begin-
ning to understand the molecular details of their function,
and the next few years should bring a fuller understanding
of how evolution has put them to work.
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